期刊
MOLECULAR PHARMACEUTICS
卷 9, 期 12, 页码 3543-3550出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp300382n
关键词
ceria nanoparticles; PET; pharmacokinetics; in vivo evaluation; rodent
资金
- Spanish MICINN [CTQ-2009-11586, CTQ2006-06785, CTQ2007-67805-AR07, PI10/1195, AP192/11]
- Fondo de Investigacion Sanitaria (FIS) of the Instituto de Salud Carlos III [PI10/1195, PS09/02620, PS09/02217]
- Generalitat Valenciana [ACOMP/2012/045]
- La Marato Fundation [090530]
- CDTI under the CENIT Programme
- Spanish Ministry of Science and Innovation
- Regional Ministry of Health of the Valencian Regional Government
- Carlos III Health Institute [CES10/030]
A variety of nanoparticles have been proposed for several biomedical applications. To gauge the therapeutic potential of these nanoparticles, in vivo biodistribution is essential and mandatory. In the present study, ceria nanoparticles (5 nm average particle size) were labeled with F-18 to study their in vivo biodistribution in rats by positron emission tomography (PET). The F-18 isotope was anchored by reaction of N-succinimidyl 4-[F-18]fluorobenzoate (F-18-SFB) with a modified nanoparticle surface obtained by silylation with 3-aminopropylsilyl. Radiolabeled ceria nanoparticles accumulated mainly in lungs, spleen, and liver. Metabolic products of the radiolabeled nanoparticulate material were excreted into the urinary tract.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据